MX2021011269A - Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. - Google Patents

Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.

Info

Publication number
MX2021011269A
MX2021011269A MX2021011269A MX2021011269A MX2021011269A MX 2021011269 A MX2021011269 A MX 2021011269A MX 2021011269 A MX2021011269 A MX 2021011269A MX 2021011269 A MX2021011269 A MX 2021011269A MX 2021011269 A MX2021011269 A MX 2021011269A
Authority
MX
Mexico
Prior art keywords
pridopidine
disorders
treatment
associated diseases
including symptoms
Prior art date
Application number
MX2021011269A
Other languages
English (en)
Inventor
Michal Geva
Michael Hayden
Rego Ana Cristina Carvalho
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of MX2021011269A publication Critical patent/MX2021011269A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un método para tratar a un sujeto que padece una enfermedad o trastorno asociado con una disfunción mitocondrial, que comprende administrar al sujeto una composición que comprende pridopidina o una sal farmacéuticamente aceptable de la misma.
MX2021011269A 2019-03-15 2020-03-15 Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. MX2021011269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962818796P 2019-03-15 2019-03-15
PCT/IL2020/050308 WO2020188558A1 (en) 2019-03-15 2020-03-15 Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine

Publications (1)

Publication Number Publication Date
MX2021011269A true MX2021011269A (es) 2021-10-01

Family

ID=72520603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011269A MX2021011269A (es) 2019-03-15 2020-03-15 Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.

Country Status (10)

Country Link
US (1) US20210220342A1 (es)
EP (1) EP3937937A4 (es)
JP (1) JP7296472B2 (es)
CN (1) CN113597310A (es)
AU (3) AU2020243692B2 (es)
BR (1) BR112021018262A2 (es)
CA (1) CA3128250C (es)
IL (1) IL286268A (es)
MX (1) MX2021011269A (es)
WO (1) WO2020188558A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023062632A1 (en) * 2021-10-11 2023-04-20 Prilenia Neurotherapeutics Ltd. Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
EP4124338A1 (en) * 2021-07-30 2023-02-01 Université de Montpellier Sigma-1 receptor activator for use in the treatment of a pathology associated with wfs1 mutation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140024677A1 (en) * 2012-04-09 2014-01-23 Musc Foundation For Research Development Methods for inducing mitochondrial biogenesis
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
AU2017223838B2 (en) * 2016-02-24 2022-09-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
US11760733B2 (en) * 2017-04-23 2023-09-19 Washington University Small molecule regulators of mitochondrial fusion and methods of use thereof
EP3634422A4 (en) * 2017-05-11 2021-05-26 Ramot at Tel-Aviv University Ltd. LEUKODYSTROPHY TREATMENT METHODS

Also Published As

Publication number Publication date
CN113597310A (zh) 2021-11-02
AU2020243692B2 (en) 2023-03-02
CA3128250C (en) 2024-01-16
CA3128250A1 (en) 2020-09-24
US20210220342A1 (en) 2021-07-22
BR112021018262A2 (pt) 2022-02-01
JP7296472B2 (ja) 2023-06-22
EP3937937A4 (en) 2022-11-23
EP3937937A1 (en) 2022-01-19
JP2022525602A (ja) 2022-05-18
AU2020243692A1 (en) 2021-10-07
WO2020188558A1 (en) 2020-09-24
IL286268A (en) 2021-10-31
AU2023203434A1 (en) 2023-06-29
AU2023203435A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2019012884A (es) Terapia de combinacion.
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
EA201891374A1 (ru) Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
MX2015006120A (es) Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos.
MX2021006985A (es) Metodos para el tratamiento de la depresión.
MX2016009231A (es) Administracion de tasimelteon en condiciones de ayuno.
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2021002322A (es) Nuevos metodos.
MD20170025A2 (ro) Tratamente terapeutice pe bază de anamorelin
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений